Who should be tested for elevated Lipoprotein(a) levels?
The European Atherosclerotic Society suggests that Lipoprotein(a) should be measured once in all subjects at intermediate or high risk of CVD or CHD (coronary heart disease) who present with¹:
- Premature CVD
- Family hypercholesterolaemia
- A family history of premature CVD and/or elevated Lipoprotein(a)
- Recurrent CVD despite statin treatment
- ≥3% 10-year risk of fatal CVD according to the European guidelines
- ≥10% 10-year risk of fatal and/or non-fatal CHD according to the US guidelines
There are also a number of health conditions that have been linked to elevated levels of Lipoprotein(a) therefore patients affected by the below should also be considered for Lipoprotein(a) monitoring:
- Chronic renal failure
- Oestrogen depletion
- Uncontrolled diabetes
As demonstrated by the above, a high proportion of patients could be affected by elevated levels of Lipoprotein(a), making this test an essential addition to the laboratory’s testing panel. Using Randox Lipoprotein(a) will ensure the accurate identification of at risk patients, enabling timely and appropriate intervention to be implemented.